Psoriasis: from pathogenesis to novel therapeutic approaches.

Psoriasis is one of the commonest chronic inflammatory disorders. Its cause is unknown, but a wealth of studies indicate that the disease results from a complex and dynamic interplay between genetic and environmental factors that trigger an excessive inflammatory response in the skin. Dendritic cells and effector T-cells are central in the development of the psoriastic lesion, and cytokines produced by these cells stimulate keratinocytes to proliferate and increase the migration of inflammatory cells into the skin, promoting epidermal hyperplasia and inflammation. Understanding the immunology of the psoriatic plaque has led to new therapeutic options and novel candidates for immunomodulation, and has changed the ways psoriatic patients are managed.

[1]  A. Blauvelt,et al.  Circulating Th17, Th22, and Th1 cells are increased in psoriasis. , 2010, The Journal of investigative dermatology.

[2]  K. Asadullah,et al.  The Th17 cytokine IL‐22 induces IL‐20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis , 2009, European journal of immunology.

[3]  J. Dreiher,et al.  Coeliac disease associated with psoriasis , 2009, The British journal of dermatology.

[4]  S. Durham,et al.  Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. , 2009, The Journal of clinical investigation.

[5]  L. Moreland,et al.  Certolizumab pegol in active rheumatoid arthritis , 2009, Current rheumatology reports.

[6]  J. Gudjonsson,et al.  Psoriasis--as an autoimmune disease caused by molecular mimicry. , 2009, Trends in immunology.

[7]  Frank O. Nestle,et al.  Skin immune sentinels in health and disease , 2009, Nature Reviews Immunology.

[8]  K. Gordon,et al.  Long‐term efficacy of biologics in the treatment of psoriasis: what do we really know? , 2009, Dermatologic therapy.

[9]  S. Chimenti,et al.  Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis , 2009, Nature Medicine.

[10]  Courtney I. Jarvis,et al.  Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis , 2009, The Annals of pharmacotherapy.

[11]  Andrew Blauvelt,et al.  Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. , 2009, The Journal of investigative dermatology.

[12]  A. Levine,et al.  IL-6 Signaling in Psoriasis Prevents Immune Suppression by Regulatory T Cells1 , 2009, The Journal of Immunology.

[13]  G. Chan,et al.  Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. , 2009, The Journal of investigative dermatology.

[14]  M. Gilliet,et al.  Self-RNA–antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8 , 2009, The Journal of experimental medicine.

[15]  Pilar Romero,et al.  IL‐17‐producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17‐related cytokines , 2009, Journal of leukocyte biology.

[16]  D. West,et al.  Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. , 2009, The Lancet. Oncology.

[17]  H. Spits,et al.  Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from TH-17, TH1 and TH2 cells , 2009, Nature Immunology.

[18]  D. Jarrossay,et al.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells , 2009, Nature Immunology.

[19]  J. Schmitt,et al.  Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Dovepress Targeted Treatment of Psoriasis with Adalimumab: a Critical Appraisal Based on a Systematic Review of the Literature , 2022 .

[20]  F. Nestle,et al.  The IL-23/Th17 axis in the immunopathogenesis of psoriasis. , 2009, The Journal of investigative dermatology.

[21]  L. Kircik,et al.  Anti-TNF agents for the treatment of psoriasis. , 2009, Journal of drugs in dermatology : JDD.

[22]  A. Rivkin Certolizumab pegol for the management of Crohn's disease in adults. , 2009, Clinical therapeutics.

[23]  L. Boon,et al.  Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis1 , 2009, The Journal of Immunology.

[24]  N. Yawalkar,et al.  Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. , 2009, Journal of dermatological science.

[25]  S. Chimenti,et al.  Efficacy of Efalizumab in Psoriasis Patients Previously Treated with Tumour Necrosis Factor Blockers , 2009, Dermatology.

[26]  R. Flavell,et al.  How are T(H)1 and T(H)2 effector cells made? , 2009, Current opinion in immunology.

[27]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[28]  H. Volk,et al.  IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not , 2009, Journal of Molecular Medicine.

[29]  Andrea W. M. Evers,et al.  β-Defensin-2 Protein Is a Serum Biomarker for Disease Activity in Psoriasis and Reaches Biologically Relevant Concentrations in Lesional Skin , 2009, PloS one.

[30]  Lisa C. Zaba,et al.  Resident and "inflammatory" dendritic cells in human skin. , 2009, The Journal of investigative dermatology.

[31]  Gonçalo Abecasis,et al.  Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis , 2009, Nature Genetics.

[32]  Pui-Yan Kwok,et al.  Genomewide Scan Reveals Association of Psoriasis with IL-23 and NF-κB Pathways , 2008, Nature Genetics.

[33]  F. Ginhoux,et al.  Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells , 2008, Nature Reviews Immunology.

[34]  Lisa C. Zaba,et al.  Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.

[35]  S. Echigo,et al.  A polymer-type water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells , 2008, Innate immunity.

[36]  Zhu Shen,et al.  Dynamic frequency of CD4+CD25+Foxp3+ Treg cells in psoriasis vulgaris. , 2008, Journal of dermatological science.

[37]  L. Cosmi,et al.  Human interleukin 17–producing cells originate from a CD161+CD4+ T cell precursor , 2008, The Journal of experimental medicine.

[38]  M. Gilliet,et al.  Antimicrobial peptides and self-DNA in autoimmune skin inflammation. , 2008, Current opinion in immunology.

[39]  Stefan Jenisch,et al.  Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. , 2008, The Journal of investigative dermatology.

[40]  T. Macdonald,et al.  Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. , 2008, Trends in immunology.

[41]  M. Lebwohl,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) , 2008, The Lancet.

[42]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[43]  D. Littman,et al.  The differentiation of human TH-17 cells requires transforming growth factor-β and induction of the nuclear receptor RORγt , 2008, Nature Immunology.

[44]  Sen Yang,et al.  Fine Mapping of the Psoriasis Susceptibility Locus PSORS1 Supports HLA-C as the Susceptibility Gene in the Han Chinese Population , 2008, PLoS genetics.

[45]  L. Fouser,et al.  IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. , 2008, The Journal of clinical investigation.

[46]  A. Kimball,et al.  Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. , 2008, Archives of dermatology.

[47]  Chen Dong,et al.  T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. , 2008, Immunity.

[48]  A. Gottlieb,et al.  A multicenter, open‐label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis , 2008, The Journal of dermatological treatment.

[49]  Lisa C. Zaba,et al.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses , 2007, The Journal of experimental medicine.

[50]  J. Kere,et al.  The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice. , 2007, Human molecular genetics.

[51]  D. Littman,et al.  Transcriptional regulation of Th17 cell differentiation. , 2007, Seminars in immunology.

[52]  I. Mellman,et al.  Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide , 2007, Nature.

[53]  Khusru Asadullah,et al.  Immunopathogenesis of psoriasis , 2007, Experimental dermatology.

[54]  Kathleen M. Smith,et al.  Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.

[55]  A. Menter,et al.  Current and future management of psoriasis , 2007, The Lancet.

[56]  Frank O. Nestle,et al.  Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis , 2007, Human Genetics.

[57]  J. Sprent,et al.  Cytokines and T cell homeostasis. , 2007, Immunology letters.

[58]  S. Chimenti,et al.  A classification of psoriasis vulgaris according to phenotype , 2007, The British journal of dermatology.

[59]  N. Van Rooijen,et al.  Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. , 2006, The Journal of clinical investigation.

[60]  M. Pasparakis,et al.  Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. , 2006, The Journal of clinical investigation.

[61]  S. Chimenti,et al.  Identical TCR β-Chain Rearrangements in Streptococcal Angina and Skin Lesions of Patients with Psoriasis Vulgaris1 , 2006, The Journal of Immunology.

[62]  L. van der Fits,et al.  Peptidoglycan and peptidoglycan‐specific Th1 cells in psoriatic skin lesions , 2006, The Journal of pathology.

[63]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[64]  Stefan Jenisch,et al.  Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. , 2006, American journal of human genetics.

[65]  H. Young,et al.  Impaired Langerhans cell migration in psoriasis , 2006, The Journal of experimental medicine.

[66]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[67]  O. Arican,et al.  Serum Levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in Patients With Active Psoriasis and Correlation With Disease Severity , 2005, Mediators of inflammation.

[68]  C. Bernstein,et al.  The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. , 2005, Gastroenterology.

[69]  O. Boyman,et al.  Plasmacytoid predendritic cells initiate psoriasis through interferon-α production , 2005, The Journal of experimental medicine.

[70]  Matthew H Samore,et al.  The Research on Adverse Drug Events and Reports (RADAR) project. , 2005, JAMA.

[71]  S. Stevens,et al.  Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation1 , 2005, The Journal of Immunology.

[72]  J. Gudjonsson,et al.  Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin‐homing CD8+ T cells , 2004, Clinical and experimental immunology.

[73]  R. Trembath,et al.  An update on the genetics of psoriasis. , 2004, Dermatologic clinics.

[74]  A. Gottlieb,et al.  Common clinical features and disease mechanisms of psoriasis and psoriatic arthritis , 2004, Current rheumatology reports.

[75]  David J Margolis,et al.  Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.

[76]  Frank O. Nestle,et al.  Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-α , 2004, The Journal of experimental medicine.

[77]  M. Dhodapkar,et al.  Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris , 2004, The Journal of experimental medicine.

[78]  D. Gladman,et al.  CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. , 2003, American journal of human genetics.

[79]  B. Sigurgeirsson,et al.  Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study , 2003 .

[80]  A. Andoh,et al.  Increased expression of interleukin 17 in inflammatory bowel disease , 2003, Gut.

[81]  W. Gulliver,et al.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.

[82]  C. Griffiths,et al.  Natural killer and natural killer-T cells in psoriasis , 2002, Archives of Dermatological Research.

[83]  Y. Ishigatsubo,et al.  Resolution of psoriasis following allogeneic bone marrow transplantation for chronic myelogenous leukemia: Case report and review of the literature , 2002, American journal of hematology.

[84]  R. Trembath,et al.  Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. , 2002, American journal of human genetics.

[85]  T. Ruzicka,et al.  Role of Integrin αE(CD103)β7 for Tissue-Specific Epidermal Localization of CD8+ T Lymphocytes , 2001 .

[86]  R. Vaughan,et al.  Corneodesmosin Expression in Psoriasis Vulgaris Differs from Normal Skin and Other Inflammatory Skin Disorders , 2001, Laboratory Investigation.

[87]  K. Takabayashi,et al.  Increased interleukin-17 production in patients with systemic sclerosis. , 2000, Arthritis and rheumatism.

[88]  S. Porcelli,et al.  Overexpression of CD1d by Keratinocytes in Psoriasis and CD1d-Dependent IFN-γ Production by NK-T Cells1 , 2000, The Journal of Immunology.

[89]  C. Wong,et al.  Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus , 2000, Lupus.

[90]  C. Albanesi,et al.  Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and interleukin-4-induced activation of human keratinocytes. , 2000, The Journal of investigative dermatology.

[91]  A. Downs,et al.  Exacerbation of psoriasis by interferon‐alpha therapy for hepatitis C , 2000, Clinical and experimental dermatology.

[92]  J. Kere,et al.  A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. , 2000, Human molecular genetics.

[93]  P. Kivisäkk,et al.  Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis , 1999, Multiple sclerosis.

[94]  N. Yawalkar,et al.  Expression of interleukin-12 is increased in psoriatic skin. , 1998, The Journal of investigative dermatology.

[95]  A. Bowcock,et al.  The genetics of psoriasis: a complex disorder of the skin and immune system. , 1998, Human molecular genetics.

[96]  J. Snowden,et al.  Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity , 1997, The British journal of dermatology.

[97]  A. Gottlieb,et al.  PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy , 1994, The Journal of experimental medicine.

[98]  D. Duffy,et al.  Psoriasis in Australian twins. , 1993, Journal of the American Academy of Dermatology.

[99]  B. Weinshenker,et al.  Remission of psoriatic lesions with muromonab-CD3 (orthoclone OKT3) treatment. , 1989, Journal of the American Academy of Dermatology.

[100]  古賀 千律子 Possible pathogenic role of Th17 cells for atopic dermatitis , 2011 .

[101]  A. Boada,et al.  A new era in the management of psoriasis? The biologics: facts and controversies. , 2010, Clinics in dermatology.

[102]  J. Weinberg Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial , 2010 .

[103]  G. Plosker,et al.  Efalizumab , 2009, American journal of clinical dermatology.

[104]  L. Castelo-Soccio,et al.  Long‐term efficacy of biologics in dermatology , 2009, Dermatologic therapy.

[105]  G. Galbraith Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis , 2008 .

[106]  B. Thiers α1β1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis , 2008 .

[107]  G. Galbraith Identical TCR β-Chain Rearrangements in Streptococcal Angina and Skin Lesions of Patients with Psoriasis VulgarisDiluvio L, Vollmer S, Besgen P, et al (Ludwig-Maximilians-Univof Munich; Univ of Rome “Tor Vergata”; GSF-Research Ctr for Environment and Health, Munich) J Immunol 176:7104–7111, 2006§ , 2007 .

[108]  L. Naldi,et al.  Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. , 2006, Clinical and experimental rheumatology.

[109]  J. Pietrzyk,et al.  Family studies in psoriasis , 2004, Archives of Dermatological Research.

[110]  J. Voorhees,et al.  Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes. , 1995, The Journal of clinical investigation.

[111]  H. E. Hansen,et al.  Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. , 1982, Acta dermato-venereologica.